 Shyam Raghavan
Concepts (279)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Skin Neoplasms | 23 | 2026 | 850 | 7.820 |
Why?
| | Melanoma | 7 | 2024 | 759 | 3.050 |
Why?
| | Nevus, Epithelioid and Spindle Cell | 5 | 2026 | 14 | 2.520 |
Why?
| | Biomarkers, Tumor | 11 | 2026 | 1321 | 2.380 |
Why?
| | Antigens, Neoplasm | 4 | 2024 | 272 | 1.500 |
Why?
| | Nevus, Pigmented | 2 | 2024 | 35 | 1.430 |
Why?
| | Proto-Oncogene Proteins B-raf | 4 | 2026 | 224 | 1.280 |
Why?
| | Diagnosis, Differential | 12 | 2024 | 1507 | 1.040 |
Why?
| | Leukemic Infiltration | 1 | 2025 | 11 | 0.930 |
Why?
| | Tendons | 5 | 2016 | 130 | 0.930 |
Why?
| | Genes, T-Cell Receptor gamma | 2 | 2021 | 3 | 0.880 |
Why?
| | Merkel cell polyomavirus | 1 | 2024 | 4 | 0.850 |
Why?
| | Carcinoma, Merkel Cell | 1 | 2024 | 16 | 0.840 |
Why?
| | Immunohistochemistry | 8 | 2024 | 1710 | 0.820 |
Why?
| | Cloning, Molecular | 2 | 2021 | 535 | 0.810 |
Why?
| | Nevus | 1 | 2024 | 26 | 0.810 |
Why?
| | Melanocytes | 2 | 2022 | 65 | 0.800 |
Why?
| | Leukemia | 1 | 2025 | 246 | 0.770 |
Why?
| | Xeroderma Pigmentosum | 1 | 2022 | 9 | 0.730 |
Why?
| | Granular Cell Tumor | 1 | 2022 | 8 | 0.710 |
Why?
| | Hamartoma | 1 | 2022 | 29 | 0.710 |
Why?
| | Pityriasis Lichenoides | 1 | 2021 | 1 | 0.710 |
Why?
| | Genes, T-Cell Receptor beta | 1 | 2021 | 23 | 0.700 |
Why?
| | Pathologists | 1 | 2022 | 19 | 0.700 |
Why?
| | Mycosis Fungoides | 2 | 2018 | 62 | 0.700 |
Why?
| | Oncogene Proteins, Fusion | 2 | 2020 | 212 | 0.690 |
Why?
| | Tissue Engineering | 5 | 2016 | 441 | 0.690 |
Why?
| | Rhabdoid Tumor | 1 | 2022 | 102 | 0.690 |
Why?
| | Lymphoproliferative Disorders | 1 | 2021 | 57 | 0.680 |
Why?
| | Syphilis | 1 | 2021 | 38 | 0.670 |
Why?
| | Bone Neoplasms | 1 | 2024 | 256 | 0.670 |
Why?
| | Carcinoma | 1 | 2022 | 224 | 0.660 |
Why?
| | Carcinoma, Adenoid Cystic | 1 | 2020 | 19 | 0.660 |
Why?
| | Lymphoid Enhancer-Binding Factor 1 | 1 | 2020 | 6 | 0.660 |
Why?
| | Sarcoma, Clear Cell | 1 | 2020 | 10 | 0.650 |
Why?
| | Keratin-7 | 1 | 2020 | 3 | 0.640 |
Why?
| | Eyelid Neoplasms | 1 | 2020 | 10 | 0.640 |
Why?
| | Carcinoma, Signet Ring Cell | 1 | 2020 | 17 | 0.630 |
Why?
| | Immunocompromised Host | 1 | 2021 | 202 | 0.620 |
Why?
| | Skin Diseases | 1 | 2021 | 152 | 0.610 |
Why?
| | Rhabdomyosarcoma, Alveolar | 1 | 2019 | 7 | 0.600 |
Why?
| | Oligodendrocyte Transcription Factor 2 | 1 | 2019 | 23 | 0.600 |
Why?
| | Receptors, Androgen | 1 | 2020 | 148 | 0.580 |
Why?
| | Ki-1 Antigen | 1 | 2018 | 7 | 0.580 |
Why?
| | Humans | 59 | 2026 | 145491 | 0.570 |
Why?
| | Cadherins | 1 | 2020 | 200 | 0.560 |
Why?
| | Ki-67 Antigen | 1 | 2018 | 117 | 0.550 |
Why?
| | Skin | 5 | 2024 | 766 | 0.550 |
Why?
| | Lymphoma, T-Cell, Cutaneous | 1 | 2018 | 45 | 0.530 |
Why?
| | Exanthema | 3 | 2023 | 86 | 0.520 |
Why?
| | Antigens, CD | 1 | 2020 | 557 | 0.500 |
Why?
| | Tissue Scaffolds | 4 | 2016 | 223 | 0.490 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2018 | 337 | 0.480 |
Why?
| | Kidney Transplantation | 1 | 2021 | 711 | 0.440 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2018 | 536 | 0.420 |
Why?
| | Mastectomy | 1 | 2015 | 181 | 0.400 |
Why?
| | Skin Abnormalities | 2 | 2023 | 12 | 0.400 |
Why?
| | Cell Proliferation | 2 | 2020 | 2499 | 0.390 |
Why?
| | Aged | 14 | 2024 | 26125 | 0.380 |
Why?
| | Mammaplasty | 1 | 2015 | 141 | 0.370 |
Why?
| | Male | 24 | 2026 | 72817 | 0.360 |
Why?
| | Foot | 2 | 2023 | 101 | 0.360 |
Why?
| | Proto-Oncogene Proteins c-sis | 1 | 2012 | 38 | 0.360 |
Why?
| | Female | 29 | 2024 | 78763 | 0.360 |
Why?
| | Aged, 80 and over | 9 | 2024 | 8326 | 0.350 |
Why?
| | Fibroblast Growth Factor 2 | 1 | 2012 | 93 | 0.340 |
Why?
| | Appendix | 1 | 2021 | 31 | 0.340 |
Why?
| | Gastrointestinal Stromal Tumors | 1 | 2021 | 41 | 0.340 |
Why?
| | Mutation | 5 | 2024 | 4093 | 0.340 |
Why?
| | Adipose Tissue | 2 | 2013 | 644 | 0.330 |
Why?
| | Stem Cells | 2 | 2013 | 626 | 0.330 |
Why?
| | DNA Mutational Analysis | 2 | 2024 | 409 | 0.330 |
Why?
| | Drug Eruptions | 2 | 2020 | 28 | 0.330 |
Why?
| | Middle Aged | 16 | 2026 | 36176 | 0.320 |
Why?
| | Stomach Neoplasms | 1 | 2021 | 130 | 0.310 |
Why?
| | Duodenum | 3 | 2024 | 77 | 0.300 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2012 | 317 | 0.300 |
Why?
| | High-Throughput Nucleotide Sequencing | 3 | 2021 | 553 | 0.290 |
Why?
| | Postoperative Complications | 1 | 2021 | 2962 | 0.290 |
Why?
| | Adult | 14 | 2026 | 40707 | 0.250 |
Why?
| | Intestinal Diseases | 2 | 2024 | 43 | 0.240 |
Why?
| | Fibroblasts | 1 | 2012 | 1023 | 0.240 |
Why?
| | Gene Fusion | 1 | 2026 | 30 | 0.240 |
Why?
| | Celiac Disease | 3 | 2024 | 310 | 0.230 |
Why?
| | Pancreatic Neoplasms | 2 | 2024 | 928 | 0.230 |
Why?
| | Prognosis | 3 | 2024 | 4323 | 0.220 |
Why?
| | Soft Tissue Neoplasms | 2 | 2021 | 128 | 0.220 |
Why?
| | Antigens, Viral, Tumor | 1 | 2024 | 7 | 0.210 |
Why?
| | Hematoxylin | 1 | 2024 | 8 | 0.210 |
Why?
| | Eosine Yellowish-(YS) | 1 | 2024 | 10 | 0.210 |
Why?
| | Extremities | 2 | 2024 | 141 | 0.210 |
Why?
| | Polyomavirus Infections | 1 | 2024 | 30 | 0.210 |
Why?
| | Necrobiosis Lipoidica | 1 | 2023 | 2 | 0.200 |
Why?
| | Livedo Reticularis | 1 | 2023 | 4 | 0.200 |
Why?
| | Tattooing | 1 | 2023 | 12 | 0.200 |
Why?
| | Leg | 2 | 2023 | 244 | 0.200 |
Why?
| | Carcinoma, Pancreatic Ductal | 2 | 2024 | 294 | 0.190 |
Why?
| | Esophagogastric Junction | 1 | 2022 | 56 | 0.190 |
Why?
| | Comparative Genomic Hybridization | 1 | 2022 | 28 | 0.180 |
Why?
| | Insulins | 1 | 2023 | 38 | 0.180 |
Why?
| | Child | 8 | 2024 | 22680 | 0.180 |
Why?
| | S100 Proteins | 1 | 2022 | 35 | 0.180 |
Why?
| | Child, Preschool | 6 | 2024 | 11837 | 0.180 |
Why?
| | Retrospective Studies | 6 | 2024 | 17269 | 0.180 |
Why?
| | Lymphoma, T-Cell | 1 | 2021 | 29 | 0.170 |
Why?
| | Lymphoma, Primary Cutaneous Anaplastic Large Cell | 1 | 2021 | 1 | 0.170 |
Why?
| | Mesenchymoma | 1 | 2021 | 9 | 0.170 |
Why?
| | Uveitis, Anterior | 1 | 2021 | 27 | 0.170 |
Why?
| | DNA Helicases | 1 | 2022 | 141 | 0.170 |
Why?
| | Pemphigus | 1 | 2021 | 8 | 0.170 |
Why?
| | Erythema | 1 | 2021 | 28 | 0.170 |
Why?
| | Skin Diseases, Vesiculobullous | 1 | 2021 | 17 | 0.170 |
Why?
| | Liposarcoma, Myxoid | 1 | 2021 | 10 | 0.170 |
Why?
| | Transcription Factor CHOP | 1 | 2021 | 32 | 0.160 |
Why?
| | Nevus, Blue | 1 | 2020 | 2 | 0.160 |
Why?
| | Dysplastic Nevus Syndrome | 1 | 2020 | 2 | 0.160 |
Why?
| | Biopsy | 2 | 2024 | 1081 | 0.160 |
Why?
| | Phospholipids | 1 | 2022 | 216 | 0.160 |
Why?
| | Scrotum | 1 | 2020 | 25 | 0.160 |
Why?
| | Histiocytes | 1 | 2020 | 7 | 0.160 |
Why?
| | Lymphoma, B-Cell | 1 | 2022 | 137 | 0.160 |
Why?
| | Carcinoma, Transitional Cell | 1 | 2020 | 69 | 0.160 |
Why?
| | Smooth Muscle Tumor | 1 | 2020 | 6 | 0.160 |
Why?
| | Ubiquitin Thiolesterase | 1 | 2020 | 68 | 0.160 |
Why?
| | Adolescent | 6 | 2022 | 22485 | 0.150 |
Why?
| | Combined Modality Therapy | 2 | 2020 | 1269 | 0.150 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2020 | 223 | 0.150 |
Why?
| | Paired Box Transcription Factors | 1 | 2019 | 43 | 0.150 |
Why?
| | Ehlers-Danlos Syndrome | 1 | 2019 | 16 | 0.150 |
Why?
| | Gastrointestinal Neoplasms | 1 | 2020 | 71 | 0.150 |
Why?
| | Myositis, Inclusion Body | 1 | 2019 | 11 | 0.150 |
Why?
| | Immunoglobulin Light-chain Amyloidosis | 1 | 2019 | 10 | 0.150 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2022 | 265 | 0.150 |
Why?
| | Intestinal Perforation | 1 | 2019 | 46 | 0.150 |
Why?
| | Hodgkin Disease | 1 | 2021 | 171 | 0.150 |
Why?
| | Eosinophilic Esophagitis | 1 | 2023 | 331 | 0.140 |
Why?
| | Surgical Flaps | 1 | 2020 | 142 | 0.140 |
Why?
| | Sjogren's Syndrome | 1 | 2019 | 37 | 0.140 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2020 | 192 | 0.140 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2020 | 254 | 0.140 |
Why?
| | beta Catenin | 1 | 2020 | 253 | 0.140 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2020 | 201 | 0.140 |
Why?
| | Tumor Suppressor Proteins | 1 | 2020 | 320 | 0.140 |
Why?
| | Nuclear Proteins | 1 | 2022 | 743 | 0.130 |
Why?
| | Urinary Bladder Neoplasms | 1 | 2020 | 260 | 0.130 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2020 | 431 | 0.130 |
Why?
| | Proto-Oncogene Proteins | 1 | 2020 | 620 | 0.130 |
Why?
| | Autoimmune Diseases | 1 | 2021 | 469 | 0.120 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2021 | 644 | 0.120 |
Why?
| | Hospitals, County | 1 | 2016 | 11 | 0.120 |
Why?
| | Carrier Proteins | 1 | 2020 | 733 | 0.120 |
Why?
| | Pericardium | 1 | 2016 | 59 | 0.120 |
Why?
| | Wrist Injuries | 1 | 2016 | 23 | 0.120 |
Why?
| | Peripheral Nerve Injuries | 1 | 2016 | 40 | 0.120 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2022 | 1150 | 0.120 |
Why?
| | Lacerations | 1 | 2016 | 40 | 0.120 |
Why?
| | Sensitivity and Specificity | 1 | 2020 | 2002 | 0.110 |
Why?
| | RNA | 1 | 2022 | 929 | 0.110 |
Why?
| | Organ Sparing Treatments | 1 | 2015 | 37 | 0.110 |
Why?
| | Cohort Studies | 3 | 2024 | 5992 | 0.110 |
Why?
| | Lower Extremity | 3 | 2023 | 446 | 0.110 |
Why?
| | Pakistan | 2 | 2024 | 79 | 0.110 |
Why?
| | Zambia | 2 | 2024 | 58 | 0.110 |
Why?
| | Transcription Factors | 1 | 2022 | 1733 | 0.110 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2020 | 994 | 0.100 |
Why?
| | Breast | 1 | 2015 | 157 | 0.100 |
Why?
| | Intestinal Mucosa | 3 | 2024 | 675 | 0.100 |
Why?
| | Microvessels | 1 | 2015 | 98 | 0.100 |
Why?
| | Antibodies, Monoclonal | 1 | 2020 | 1511 | 0.100 |
Why?
| | Transcriptome | 1 | 2019 | 1038 | 0.090 |
Why?
| | T-Lymphocytes | 1 | 2020 | 1996 | 0.090 |
Why?
| | Patient Compliance | 1 | 2016 | 587 | 0.090 |
Why?
| | Polymers | 2 | 2023 | 494 | 0.090 |
Why?
| | Inflammation | 1 | 2023 | 2883 | 0.080 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2011 | 325 | 0.080 |
Why?
| | Collagen | 1 | 2013 | 453 | 0.080 |
Why?
| | Drug Synergism | 1 | 2012 | 353 | 0.080 |
Why?
| | Bioreactors | 1 | 2011 | 51 | 0.080 |
Why?
| | Rabbits | 1 | 2011 | 651 | 0.080 |
Why?
| | Rats, Wistar | 1 | 2011 | 449 | 0.080 |
Why?
| | Vascular Neoplasms | 1 | 2009 | 18 | 0.070 |
Why?
| | Angioplasty | 1 | 2009 | 50 | 0.070 |
Why?
| | Extracellular Matrix | 2 | 2024 | 562 | 0.070 |
Why?
| | Retroperitoneal Neoplasms | 1 | 2009 | 28 | 0.070 |
Why?
| | Esophagus | 1 | 2021 | 262 | 0.070 |
Why?
| | Tumor Microenvironment | 2 | 2024 | 737 | 0.070 |
Why?
| | Prospective Studies | 3 | 2023 | 8039 | 0.070 |
Why?
| | Antineoplastic Agents | 1 | 2020 | 2207 | 0.070 |
Why?
| | Vascular Surgical Procedures | 2 | 2009 | 348 | 0.070 |
Why?
| | Colon | 1 | 2021 | 308 | 0.070 |
Why?
| | Treatment Outcome | 3 | 2020 | 11831 | 0.070 |
Why?
| | Polyethyleneimine | 1 | 2008 | 19 | 0.070 |
Why?
| | Vaccines, DNA | 1 | 2008 | 32 | 0.070 |
Why?
| | Young Adult | 4 | 2020 | 14192 | 0.070 |
Why?
| | Cells, Cultured | 2 | 2013 | 4127 | 0.070 |
Why?
| | Microspheres | 1 | 2008 | 142 | 0.070 |
Why?
| | Sarcoma | 1 | 2009 | 204 | 0.060 |
Why?
| | Education, Medical, Undergraduate | 1 | 2009 | 207 | 0.060 |
Why?
| | Animals | 6 | 2023 | 38141 | 0.060 |
Why?
| | Computer Simulation | 1 | 2009 | 1026 | 0.050 |
Why?
| | Goblet Cells | 1 | 2024 | 22 | 0.050 |
Why?
| | Child Nutrition Disorders | 1 | 2024 | 20 | 0.050 |
Why?
| | Bangladesh | 1 | 2024 | 63 | 0.050 |
Why?
| | Milk Proteins | 1 | 2023 | 33 | 0.050 |
Why?
| | Antigen-Antibody Complex | 1 | 2023 | 70 | 0.050 |
Why?
| | Intestine, Small | 1 | 2024 | 167 | 0.050 |
Why?
| | Acrylamides | 1 | 2023 | 74 | 0.050 |
Why?
| | Immunoglobulin Heavy Chains | 1 | 2022 | 86 | 0.040 |
Why?
| | Risk Assessment | 1 | 2021 | 3759 | 0.040 |
Why?
| | Carcinoma, Neuroendocrine | 1 | 2021 | 37 | 0.040 |
Why?
| | In Situ Hybridization | 1 | 2022 | 318 | 0.040 |
Why?
| | Hyperplasia | 1 | 2022 | 177 | 0.040 |
Why?
| | Clinical Competence | 1 | 2009 | 1242 | 0.040 |
Why?
| | Hepatocytes | 1 | 2022 | 224 | 0.040 |
Why?
| | Genes, T-Cell Receptor | 1 | 2020 | 6 | 0.040 |
Why?
| | Molecular Diagnostic Techniques | 1 | 2022 | 104 | 0.040 |
Why?
| | CD4-CD8 Ratio | 1 | 2020 | 23 | 0.040 |
Why?
| | Lip | 1 | 2020 | 23 | 0.040 |
Why?
| | Cattle | 1 | 2023 | 977 | 0.040 |
Why?
| | Peripheral Nerves | 1 | 2020 | 72 | 0.040 |
Why?
| | Fluorescent Antibody Technique | 1 | 2021 | 364 | 0.040 |
Why?
| | Allergens | 1 | 2023 | 390 | 0.040 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2021 | 324 | 0.040 |
Why?
| | Genetic Therapy | 1 | 2022 | 316 | 0.040 |
Why?
| | Infant | 2 | 2024 | 10064 | 0.040 |
Why?
| | Immunophenotyping | 1 | 2021 | 320 | 0.040 |
Why?
| | Tertiary Care Centers | 1 | 2021 | 195 | 0.040 |
Why?
| | Fibrosis | 1 | 2022 | 551 | 0.040 |
Why?
| | Lymphatic Metastasis | 1 | 2020 | 335 | 0.040 |
Why?
| | Ileostomy | 1 | 2019 | 26 | 0.040 |
Why?
| | Immunoglobulin G | 1 | 2023 | 890 | 0.040 |
Why?
| | Cost-Benefit Analysis | 1 | 2022 | 645 | 0.040 |
Why?
| | Colectomy | 1 | 2019 | 106 | 0.040 |
Why?
| | Oxidation-Reduction | 1 | 2022 | 1080 | 0.030 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2021 | 239 | 0.030 |
Why?
| | Mice | 3 | 2023 | 18338 | 0.030 |
Why?
| | Machine Learning | 1 | 2023 | 590 | 0.030 |
Why?
| | Synoviocytes | 1 | 2016 | 18 | 0.030 |
Why?
| | San Francisco | 1 | 2016 | 60 | 0.030 |
Why?
| | Microscopy, Electron, Scanning | 1 | 2016 | 200 | 0.030 |
Why?
| | Recurrence | 1 | 2019 | 1142 | 0.030 |
Why?
| | Hydrogels | 1 | 2023 | 704 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2016 | 339 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2021 | 2129 | 0.030 |
Why?
| | Psychology | 1 | 2016 | 88 | 0.030 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2016 | 975 | 0.030 |
Why?
| | Aftercare | 1 | 2016 | 222 | 0.030 |
Why?
| | Rats | 1 | 2023 | 5581 | 0.030 |
Why?
| | Swine | 1 | 2016 | 833 | 0.030 |
Why?
| | Prevalence | 1 | 2021 | 2855 | 0.030 |
Why?
| | Liver | 1 | 2022 | 1895 | 0.020 |
Why?
| | Cell Survival | 1 | 2016 | 1094 | 0.020 |
Why?
| | Coculture Techniques | 1 | 2013 | 246 | 0.020 |
Why?
| | Disease Progression | 1 | 2020 | 2862 | 0.020 |
Why?
| | Recovery of Function | 1 | 2016 | 716 | 0.020 |
Why?
| | Social Support | 1 | 2016 | 651 | 0.020 |
Why?
| | Socioeconomic Factors | 1 | 2016 | 1327 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2022 | 5989 | 0.020 |
Why?
| | Tensile Strength | 1 | 2011 | 99 | 0.020 |
Why?
| | Elastic Modulus | 1 | 2011 | 121 | 0.020 |
Why?
| | Mental Health Services | 1 | 2016 | 472 | 0.020 |
Why?
| | Problem-Based Learning | 1 | 2009 | 97 | 0.020 |
Why?
| | Task Performance and Analysis | 1 | 2009 | 198 | 0.020 |
Why?
| | Biomechanical Phenomena | 1 | 2011 | 860 | 0.020 |
Why?
| | Career Choice | 1 | 2009 | 235 | 0.020 |
Why?
| | Microscopy, Confocal | 1 | 2008 | 318 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2019 | 3897 | 0.020 |
Why?
| | United States | 1 | 2024 | 16115 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2016 | 5426 | 0.020 |
Why?
| | Educational Measurement | 1 | 2009 | 325 | 0.020 |
Why?
| | Academic Medical Centers | 1 | 2009 | 551 | 0.020 |
Why?
| | Cell Differentiation | 1 | 2013 | 2045 | 0.010 |
Why?
| | Biomarkers | 1 | 2016 | 4283 | 0.010 |
Why?
| | Students, Medical | 1 | 2009 | 375 | 0.010 |
Why?
| | Kinetics | 1 | 2008 | 1605 | 0.010 |
Why?
| | Drug Delivery Systems | 1 | 2008 | 382 | 0.010 |
Why?
| | Flow Cytometry | 1 | 2008 | 1156 | 0.010 |
Why?
| | Cell Line | 1 | 2008 | 2823 | 0.010 |
Why?
| | Curriculum | 1 | 2009 | 1068 | 0.010 |
Why?
|
|
Raghavan's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|